口服缬更昔洛韦治疗眼压失控的巨细胞病毒性前葡萄膜炎的疗效与安全性
本研究回顾性分析了17例免疫功能正常、经PCR确诊的巨细胞病毒性前葡萄膜炎且眼压药物控制不佳的患者,接受单疗程口服缬更昔洛韦治疗。2年随访显示,超过三分之一患者避免了眼压降低手术,眼压在多个时间点显著低于基线,无严重药物相关不良事件。
要点
- 口服缬更昔洛韦可使部分CMV前葡萄膜炎伴眼压失控患者避免青光眼手术。
- 治疗2周至12个月及21、24个月眼压显著低于基线,降幅16.9-46.0%。
- 常见副作用包括单核细胞减少和肾功能/电解质异常,无严重不良事件。
核心结论
- 在眼压失控的CMV前葡萄膜炎患者中,超过三分之一经口服缬更昔洛韦治疗2年内避免了眼压降低手术。
研究设计与样本
- 回顾性病例系列,纳入17例免疫功能正常、PCR确诊的CMV前葡萄膜炎患者,每例取一眼,接受单疗程口服缬更昔洛韦20-148天,随访至2年或眼压降低手术。
主要发现
- 基线眼压中位数27.0 mmHg(IQR 22.9-31.0 mmHg),降眼压药物中位数4.0种。
- 开始缬更昔洛韦后2周至12个月及21、24个月眼压显著低于基线(p=0.001至0.041),中位降幅16.9-46.0%。
- 12个月和24个月时分别有7例(41.2%)和6例(35.3%)患者眼压≤21 mmHg且局部用药不变或减少。
- 至眼压降低干预或第二疗程缬更昔洛韦的中位时间为12.4个月。
- 常见副作用为单核细胞减少(9例)和肾功能/电解质异常(5例),无严重药物相关不良事件;诊断性前房穿刺后眼压 spike 和伤口渗漏发生率分别为35.5%和29.4%。
临床怎么用
- 对于CMV前葡萄膜炎伴药物无法控制的眼压升高,可考虑口服缬更昔洛韦单疗程治疗以降低眼压、减少手术需求。
- 治疗期间需监测单核细胞计数及肾功能和电解质。
局限性
- 回顾性病例系列,样本量小(17例),无对照组,结果需更大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: While cytomegalovirus (CMV) anterior uveitis (AU) patients often require glaucoma surgery, the effectiveness of systemic anti-viral in long-term intraocular pressure (IOP) control is not well established. Our study aims to identify the 2-year efficacy and safety of oral valganciclovir in CMV AU with uncontrolled IOP. METHODS: In this retrospective case series, one eye from each of 17 immunocompetent PCR-proven patients with CMV AU who received a single course of oral valganciclovir for 20-148 days for medically uncontrolled IOP during 2008-2018 were identified. They were examined at baseline, week 2, months 1, 2 and 3, then every 3 months up to 2 years after commencement of valganciclovir, or until IOP-lowering procedure. RESULTS: Median baseline IOP and IOP-lowering medication were 27.0 mm Hg (IQR: 22.9-31.0 mm Hg), and 4.0, respectively. IOP was significantly lower than baseline from 2 weeks to 12 months and at 21 and 24 months after starting valganciclovir (p=0.001 to 0.041, Wilcoxon sign-rank test), with 16.9-46.0% median IOP reduction. Seven (41.2%) and six (35.3%) patients had IOP≤21 mm Hg with same, or reduced, topical medications by 12 and 24 months, respectively. Median time to IOP-lowering intervention or second course of valganciclovir was 12.4 months. There was no serious medication-related adverse event. Common side effects included reduced monocyte count (9 patients) and deranged renal function/electrolytes (5 patients). IOP spike and wound leak occurred in 35.5% and 29.4% of patients, respectively, after diagnostic aqueous tap. CONCLUSION: In CMV AU with uncontrolled IOP, >1/3 of the patients avoided glaucoma surgery over 2 years with a course of oral valganciclovir.
引用
- Wong MOM, Yu AHY, Chan CKM, et al. Efficacy and safety of oral valganciclovir in cytomegalovirus anterior uveitis with uncontrolled intraocular pressure. Br J Ophthalmol. 2020. PMID: 33011687. doi:10.1136/bjophthalmol-2020-317044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。